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1. Introduction 
The association between ulcerative colitis (UC) and colorectal cancer (CRC) was first 
reported in the 1920s (Crohn & Rosenberg, 1925). Since then, numerous studies have 
confirmed the overall risk of developing colorectal cancer associated with UC, and 
inflammatory bowel disease (IBD) in general. Many studies incorporate both UC and 
Crohn’s colitis together with regards to their risk of colorectal cancer. While more recent 
studies have questioned how substantial the increased risk of colorectal cancer truly is in 
UC, relative to the general population, specific characteristics of UC patients increase their 
overall risk of developing CRC. In fact, CRC is one of the most serious complications of IBD 
and accounts for approximately 10-15% of the deaths in IBD patients (Munkholm et al, 
2003). To reduce this complication, UC related CRC screening programs should focus on the 
individuals’ risk of developing CRC with the goal of early identification of the cancer and 
subsequent increased overall survival. 
2. Risk factors for developing colorectal cancer 
Patients with UC are at an overall increased risk of developing CRC compared to the 
general population. This risk is additive to the baseline risk of developing sporadic CRC. 
The average age at diagnosis of UC related CRC ranges from 43.2 to 50.9 years (Eaden et al., 
2001a; Lakatos & Lakatos, 2006).  In addition to age, significant risk factors include the 
extent of colonic disease, age of onset and duration of disease, degree of inflammation, and 
the presence of primary sclerosing cholangitis. All these factors are crucial to prognosticate 
the patients overall risk and discuss treatment options. 
2.1 Overall risk 
While the risk of developing CRC in patients with UC is increased, the magnitude is 
challenging to estimate. Multiple studies with differing methodologies (population based 
cohorts versus populations from tertiary referral centers) have been performed and have 
reported varying risk estimates for the development of CRC. This difference may in part be 
due to the fact that some tertiary care centers opt for earlier colectomy or early therapy with 
aminosalicylates which may reduce the reported incidence of CRC. In 2001 a meta-analysis 
by Eaden and Abrams found the cumulative incidence of CRC in UC patients to be 2% at 10 
years of disease, 8% after twenty years, and 18% after thirty years of disease. However, even 
this meta-analysis may overestimate the risk of CRC given the large percentage of patients 
who were treated only in tertiary care centers. Data from the Olmsted County database in 
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the United States (US) did not find any increased risk of CRC in UC over a fourteen year 
follow up (Jess et al., 2006).  A more recent study in the Netherlands looking at 26,855 
patients with IBD (both ulcerative colitis and Crohn’s disease) under the age of 65 found an 
overall incidence of 0.04% colitis related CRC (Baars et al., 2011). Despite these varying 
estimates, it appears that there is an increased risk of developing CRC, although the exact 
number is difficult to approximate. 
2.2 Anatomic extent of disease 
Anatomic extent of disease has been reported as one of the most important predictors of 
CRC risk in UC. Extent of disease is defined by the most extensivedisease noted 
histologically or endoscopically at any time (Mathy et al., 2003). Extent of disease is usually 
classified as pancolitis, left sided colitis, proctosigmoiditis, or proctitis. The definition of left 
sided colitis, unfortunately, varies in the literature; while most studies report it to be up to 
the splenic flexure, other studies extend it to the hepatic flexure. Overall, subtotal or 
pancolitis carried a relativerisk of 14.8 to 19.2, while for left sided disease, the relative risk 
was 2.8. (Ekbom et al., 1990; Gyde et al., 1988). Isolated proctosigmoiditis or proctitis did not 
significantly increase the risk of CRC (Jess et al., 2006; Langholz et al., 1992). In more recent 
studies, presence of backwash ileitis also did not increase the risk of CRC. (Haskell et al., 
2005). The increased risk related to extent of disease is most significant in pancolitis patients 
during the first two decades of disease. By the fourth decade of disease, however, the 
incidence of CRC among pancolitis and L sided colitis equalizes (Greenstein et al., 1979; 
Gyde et al., 1988). Thus, these two groups of UC patients are recommended to undergo 
surveillance colonoscopy with biopsies given their increased risk. 
2.3 Age of onset and duration of disease  
The younger the age of onset of ulcerative colitis, the higher the patient’s risk of cancer. 
After 35 years of follow-up, patients with extensive colitis diagnosed before the age of 15 
had a cumulative risk of CRC of 40%. Patients diagnosed with UC between the ages of 15-39 
had a lower, but still substantial, cumulative risk of CRC of 25% (Ekbom et al., 2006). 
However, this increased risk has not been substantiated in all studies. Greenstein et al 
estimated that patients aged 10-19 at diagnosis of left sided or pancolitis had an incidence of 
CRC of 3.6 per 1000 patient years. This incidence was increased to 12.7 per 1000 patient 
years in patients diagnosed between ages 30-39 (Greenstein et al., 1979). A recent study 
found a small but statistically significant increased risk of CRC with duration of disease 
(Baars et al., 2011). However CRC is rarely found when disease duration is less than eight to 
ten years (Ransohoff, 1988). Even in patients with extensive colitis, no cancers were detected 
during the first decade of follow up in 1406 patient-years (Lennard-Jones et al., 1990). In 
cases where CRC was diagnosed, the mean duration of disease from time of diagnosis of UC 
was seventeen years (Pinczowski et al., 1994).  Considerations therefore for CRC screening 
due to UC are based on disease duration, not patient age. It is important to remember that in 
addition to UC related risks of CRC, UC patients also develop the same increased risk of 
age-related sporadic CRC.  
2.4 Degree of inflammation 
The severity of inflammation noted on colonoscopy is also associated with CRC. A study by 
Rutter et al reviewed patients with UC and CRC or dysplasia compared to UC patients 
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without CRC or dysplasia. Inflammation was categorized as chronic/quiescent, mild, 
moderate, or severe by colonoscopic and histologic means. In univarate analysis both 
colonoscopic and histologic signs of inflammation increased the risk of CRC (odds ratio 2.5 
and 5.1 respectively) (Rutter et al., 2004d). The increased risk was more dramatic from 
histologic scoring (Gupta et al., 2007; Rutter et al., 2004d). A similar study confirmed these 
results noting the progression from histologic inflammation to dysplasia or CRC (Rubin et 
al., 2006a). The risk of developing CRC is still present even after areas of severe mucosal 
inflammation return to normal.  
2.5 Risks among males and females 
Initial studies found no difference in the risk of developing CRC between men and 
women. (Ekbom et al., 1990). However, a more recent study of 7,607 patients of whom 
4,125 had UC, noted an overall lower risk of CRC amongst women compared to men. 
Relative to the general population women with UC still had an overall increased risk of 
CRC. However, compared to their male counterparts, women diagnosed before the age of 
forty five and with more than ten years of disease had a lower relative risk of CRC 
(Soderlund et al., 2010). 
2.6 Family history 
Just like the two to three fold increased risk of CRC in first degree relative of patients in 
the general population, having a family history of CRC further increases the UC patient’s 
risk of cancer (Askling et al., 2001; Nuako et al., 1998a). This risk was even more 
substantial when the first degree relative developed CRC prior to the age of fifty (Askling 
et al., 2001).  
2.7 Associated Primary sclerosing cholangitis (PSC) 
A small subset of patients with UC (2-5%) who develop PSC are at an even greater increased 
risk of developing CRC. This risk also increases with duration of disease. The risk of 
carcinoma or dysplasia in these patients was found to be 9% at ten years, 31% at twenty 
years, and 50% after twenty five years of disease duration (Broome et al., 1995). While some 
studies have failed to replicate this finding (Loftus et al., 1996; Nuako et al., 1998b), a meta 
analysis of studies including patients with UC and PSC found a four fold increased risk of 
CRC (Soetikno et al., 2002).  This risk of CRC was also noted even after orthotopic liver 
transplant for PSC with an approximate incidence of 1% per person year (Loftus et al., 1998). 
A study from the United Kingdom noted a much higher cumulative risk post 
transplantation with risks of 14% at five years and 17% at ten years post-transplantation 
(Vera et al., 2003). Given the dramatic increase risk of CRC associated with associated PSC, 
patients having both UC and PSC should initiate annual colonoscopy surveillance at time of 
PSC diagnosis. 
2.8 Miscellaneous risk factors 
Additional risk factors that are only noted on colonoscopy include strictures, shortened 
colon, and pseudopolyps. In a small retrospective study, true strictures were found in 15 of 
469 patients with UC. Of these fifteen patients, there were twenty seven strictures noted. 
Two were cancerous at diagnosis and twenty three showed low or high grade dysplasia. 
Ultimately, thirteen of the fifteen patients underwent colectomy, and an additional four 
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patients were found to have CRC (Lashner et al., 1990). Another retrospective study of 
hospitalized patients with UC found the prevalence of strictures to be 5%, with 24% of the 
strictures being malignant. In all of these cases, the patients had more than twenty years of 
disease (Gumaste et al., 1992). Similarly, Rutter et al found that both strictures (odds ratio of 
4.62) and post-inflammatory polyps (odds ratio of 2.29) conveyed a significantly increased 
risk of developing CRC (Rutter et al., 2004c). While post-inflammatory polyps do not 
develop directly into CRC, they are thought to act as a surrogate marker of previous severe 
inflammation which has been shown to carry significant risk of CRC (Rutter et al., 2004c).  
The risk of a malignant stricture increased with disease duration, location proximal to the 
splenic flexure, and presence of a symptomatic large bowel obstruction (Gumaste et al., 
1992). 
 
Risk factors for UC related CRC Relative Risk 
Anatomic extent of disease (pancolitis > left sided) +++ 
Duration of disease +++ 
Co-morbid Primary sclerosing cholangitis +++ 
Younger age of onset  ++ 
Inflammation + 
Stricture + 
Pseudopolyps + 
Family history of colorectal cancer + 
Male > female + 
Proctitis/Proctosigmoiditis - 
Backwash ileitis - 
Smoking - 
Table 1. Risk factors for colorectal cancer: + indicates increased risk and – indicates no 
proven increased risk 
3. Genetics of UC related CRC 
Similar to most cancers, genetic mutation, loss of function of tumor suppressor genes, 
oxidative stress, and errors in DNA mismatch repair all play critical roles in the 
development of UC associated CRC. Some of the genetic changes are similar to sporadic 
CRC, but key aspects and timing of events differ. Many of these changes occur prior to any 
detectable mucosal changes. Unlike sporadic CRC which develops in a stepwise process 
over many years, UC associated CRC can progress rapidly without a classic slow 
progression. 
3.1 Genetics of UC associated CRC 
While chronic inflammation is a risk factor for developing cancer, in UC inflammation is 
only one aspect in the pathophysiology of CRC development. For example, despite the 
inflammation seen in proctitis and proctosigmoiditis, patients with this extent of disease do 
not  convey an increased risk of cancer. The step-wise process in the development of CRC is 
similar to the well established “adenoma-carcinoma” sequence in sporadic CRC. Crypt foci 
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or mircoadenoma, progress to large adenoma, to cariconma-in-situ, and then into invasive 
adenocarcinoma. The most common cause of sporadic CRC arises from chromosomal 
instability leading to abnormal segregation of chromosomes and aneuploidy. The 
chromosomal instability leads to loss of heterozygosity and eventually loss of function of 
tumor suppressor genes. The loss of function of the APC gene is a crucial initiating event in 
the development of most adenomas.  In sporadic colorectal cancer, key underlying features 
include both chromosomal instability and microsatellite instability. Eventually there is the 
loss of the p53 tumor suppressor gene which is the transition from adenoma to carcinoma. 
The remaining 15% of sporadic CRC involve the microsatellite instability pathway involving 
the loss of function of DNA mismatch repair genes. Two of the genes commonly affected are 
hMLH1 and hMSH2.  (Itzkowitz, 2003; Itzkowitz & Yio, 2004) 
Like sporadic CRC, UC related CRC develops from sequential steps of somatic genetic 
mutation and associated clonal expansion. While the same genetic mutations occur in UC 
related CRC, the timing and frequency is different. Approximately 80% of the cancers are 
related to chromosomal instability while 20% are related to microsatellite instability. In UC 
related CRC the main genetic alteration is in the allelic deletion of p53 in 50-85% of cases 
(Itzkowitz & Yio, 2004).  In review of colectomy specimens, the p53 mutation preceded 
aneuploidy which in turn preceded p53 loss of heterzygosity (Brentnall et al., 1994). This 
loss of heterozygosity correlates with malignant progression, and is detected in 63% of low 
grade dysplasia and 85% of cases involving high grade dysplasia (Burmer et al., 1992).  The 
p53 mutation was also detected at a high frequency (>50%) in patients with UC and 
inflamed mucosa (Hussain et al., 2000). The APC mutation is extremely rare (0-3%) and only 
occurs late in high grade dysplasia or cancer (Aust et al., 2002). Similarly, allelic deletion of 
the APC gene occurs in < 33% of colitis-related neoplasia (Umetani et al., 1999). Also 
different from sporadic CRC, the k-ras mutation is quite rare in UC related CRC, while 
BRAF mutation is more common (Lakatos & Lakatos, 2008; Yashiro et al., 2001). 
Microsatellite instability occurs through the same process as in sporadic CRC, and involves 
mismatch repair defects of hMLH1, hMSH2, and hMSH6 (Lakatos & Lakatos, 2008). In 
approximately 25% of cases, microsatellite instability was demonstrated two to twelve years 
before the diagnosis of CRC (Tahara et al., 2005). 
3.2 Oxidative stress 
The role of oxidative stress from chronic inflammation seems to play some role in the 
development of UC related CRC.  Oxidative stress has multiple effects including cellular 
damage, contributing to the pathogenesis of colitis, and contributing to colon cancer 
carcinogenesis (Ullman & Itzkowitz, 2011). The chronically inflamed tissue release reactive 
oxygen and nitrogen species (RONS) from cells in the innate immune system. Actively 
inflamed tissue in UC expresses increased levels of both RONS and nitric oxide synthase 
(Hussain et al., 2000; Itzkowitz & Yio, 2004; Ullman & Itzkowitz, 2011;).  Furthermore, 
measurements of 8-hydroxydeoxyguanosine, a mutagen formed from hydroxal radicals is 
found to be increased in UC mucosa and even higher in specimens with dysplasia. . The 
formulation of free radicals affects metabolic processes that regulate DNA, RNA, proteins, 
and lipids. Once the genes or proteins affecting colonocyte homeostasis are affected, like 
p53, dysplasia and carcinoma ensue. Lastly, the oxidative stress has also been found to 
interfere with DNA mismatch repair enzymes, contributing to microsatellite instability as 
well (Ullman & Itzkowitz, 2011).  
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3.3 DNA methylation 
DNA methylation also contributes to the development and progression of colitis-related 
CRC. The resulting methylation of CpG islands in several genes occurs prior to dysplasia 
and is found diffusely in the UC mucosa (Issa et al., 2001). The hMLH1 hypermethylation is 
noted in neoplastic mucosa most commonly with high levels of MSI (46%) but is also found 
with low and no detected MSI (Fleisher et al., 2000; Ullman & Itzkowitz, 2011). 
Hypermethylation of cell cycle inhibitor p16ink14a is frequently found in neoplastic specimens 
in colitis-related cancer (Hsieh et al., 1998).  While 10% of samples without dysplasia already 
showed hypermethylation of the p16 promoter, the rates rapidly increased with degree of 
dysplasia reaching 100% in tumor samples (Ullman, 2011). Similarly, p14ARF, which is an 
indirect regulator of p53, is encoded by the same gene as p16ink14a. Loss of expression via 
hypermethylation is detected in 50% of adenocarcinoma specimens, 33% of dysplasic 
specimens, and 60% of mucosal samples with no dysplasia (Sato et al. 2002; Ullman & 
Itzkowitz, 2011). 
 
Chromosomal 
instability 
Microsatellite 
instability 
Hypermethylation Oxidative stress 
Aneuploidy hMLH1 hMLH1 Free radicals 
P53 hMSH2 p16ink14a DNA mismatch repair enzymes 
APC hMSH6 p14ARF  
Chromosomal loss 
of function 
DPC4   
Table 2. Summary of genetic changes in colitis related colorectal cancer 
4. Pathophysiology of dysplastic lesions in ulcerative colitis 
Dysplasia is currently the best indicator of CRC risk in UC ( Goldman, 1996). It is defined as 
neoplastic epithelium confined to the basement membrane that is categorized histologically 
by a mix of architectural and cytologic features (Guindi & Riddell, 2001; Riddell et al., 1983).  
75 to 90% of cancers in UC are noted to have underlying dysplasia with the classic 
progression from inflammation to dysplasia to carcinoma (Sharan & Schoen, 2002). 
However, a substantial number of colitis associated cancers arise without any preceding 
dysplasia, but even these cancers only occur in areas of chronic or active inflammation 
(Goldman, 1996; Riddell et al., 1983; Woolrich et al., 1992). In studies looking at patients who 
underwent colectomy for CRC, dysplasia was absent in up to 25% of the specimens 
(Brackmann et al., 2009; Connell et al., 1994). Consequently, the absence of dysplasia alone 
does not rule out the possibility of carcinoma. 
4.1 Classification of dysplasia 
Biopsy specimens are classified based on microscopic morphology as (1) negative for 
dysplasia, (2) indefinite for dysplasia, or (3) positive for dysplasia (Ridell, 1983). While true 
dysplasia is classified based on the degree of cytologic and architectural atypia of the crypts 
and surface epithelium, distinguishing these features can be challenging. Indefinite for 
dysplasia classifies specimens that possess some cytologic and architectural features of low 
grade dysplasia but also has active inflammation or ulceration in the area making the 
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neoplastic status unclear. The features include changes that are more extreme than expected 
in just regenerative changes, nuclear features that seem beyond those considered normal 
repair, and nuclei in quiescent disease that are larger than expected for that disease state 
(Guindi & Riddell, 2001). Once a lesion is classified as dysplastic it is further differentiated 
into (1)  low grade dysplasia, (2) high grade dysplasia, and (3) carcinoma (Riddell et al., 
1983). Because there is significant inter-observer variability among pathologists, the 
diagnosis of dysplasia must be confirmed by a second expert IBD pathologist. 
Histologically, low grade dysplasia is hallmarked by nuclear enlargement, increased nuclear 
to cytoplasmic ratio, hyperchromasia, pleomorphisms, and increased mitoses. Classically, 
the nuclei are limited to the basal half of the cell cytoplasm. High grade dysplasia is similar 
to low grade dysplasia histologically, but more severe. It has prominent nuclear 
stratification and nuclei that are larger with more open nuclear chromatin patterns 
compared to low grade dysplasia. Unlike low grade dysplasia, the mitoses are both more 
frequent and present in the upper levels of the crypts as well as the surface epithelium. 
Additional general characteristics include: hyperchromatism, crowding, pleomorphism, loss 
of polarity of nuclei, and architectural aberrations like back to back gland patterns and 
cribriforming of the crypts (Farraye et al., 2010; Guindi & Riddell, 2001). This category of 
high grade dysplasia also includes carcinoma in situ, but it is not differentiated in reports 
(Itzkowitz & Harpaz, 2004). Carcinoma is defined by the presence of cells or glands that 
penetrate through the lamina propria and or submucosa. In UC-related carcinoma, single 
cell and small gland infiltration or large dysplastic crypts with irregular jagged contours or a 
complex cribriform gland pattern are seen. Also commonly seen features include necrosis, 
hemorrhage, ulceration, and desmoplasia. Ultimately, when determining the degree of 
dysplasia, pathologists assign the level based on the most severe level of atypical portion 
found in the biopsy sample (Farraye et al., 2010).  
4.2 Dysplasia classification systems 
While the United States uses the Ridell based classification of dysplasia (negative, indefinite, 
low or high grade dysplasia), outside the US, the Vienna system is used. This system was 
developed to improve standardization of interpretation and terminology of dysplasia. It is 
slightly different than Ridell’s classification and uses a five category system. The five 
categories are: negative for neoplasia/dysplasia, indefinite for neoplasia/dysplasia, 
 
Vienna Riddell 
1. Negative for neoplasia/dysplasia 1. Negative for dysplasia 
2. Indefinite for neoplasia/dysplasia 2. Indefinite for dysplasia 
3. Noninvasive low grade neoplasia 3. Low grade dysplasia 
4. Noninvasive high grade neoplasia 
a. High grade adenoma/dysplasia 
b. Noninvasive carcinoma 
c. Suspicious of invasive carcinoma 
4. High grade dysplasia 
5. Invasive neoplasia 
a. Intramucosal adenocarcinoma 
b. Submucosal carcinoma or beyond
 
Table 3. Riddell and Vienna classification systems 
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noninvasive high-grade neoplasia, and invasive neoplasia. The last two categories are 
further sub-classified histologically (see table 3 for full details) (Schlemper et al., 2000). 
Clinically though, there are no important differences between the two classification systems. 
4.3 Risk of cancer based on degree of dysplasia 
Given that the presumed stepwise sequence of developing CRC in UC is inflammation to 
low grade dysplasia to high grade dysplasia to carcinoma, the risk of progression from 
levels of dysplasia is important to quantify to help determine surveillance 
recommendations. Indefinite for dysplasia has classically been considered to be non-
cancerous. However, newer studies question if the malignancy risk is underestimated. 
According to some studies, indefinite for dysplasia should be considered to behave like the 
subcategory low grade dysplasia (Bernstein et al., 1994). The progression from indefinite 
dysplasia to CRC ranged from 9% to 28% (Bernstein et al., 1994; Rutter et al., 2006; Ullman et 
al., 2008). In low grade dysplasia, the overall risk of cancer is reported as a 10% risk of 
invasive carcinoma (axon, 1994; Bernstein et al., 1994). Unfortunately in high grade 
dysplasia the risk is even greater, increasing to nearly 40% (Bernstein et al., 1994).  
 
Dysplasia Risk of CRC 
High grade dysplasia 
Low grade dysplasia 
Indefinite for dysplasia 
Negative for dysplasia 
+++ 
++ 
Questionable risk (could be similar to low grade dysplasia) 
No risk 
Table 4. Type of dysplasia and risk of CRC 
4.4 Dysplastic associated lesions or masses (DALM) 
Dysplasia is further sub-classified as flat or elevated lesions (Itzkowitz & Harpaz, 2004). Flat 
dysplasia is undetectable endoscopically but picked up by random biopsies, while raised is 
visualized and referred to as “DALM” (dysplastic associated lesion or mass) (Blackstone et 
al., 1981). DALMs are visible dysplastic lesions with an unacceptably high risk of carcinoma. 
In a series by Blackstone et al., 58% of these lesions had an underlying carcinoma  
 
Adenoma-like DALMs Non-adenoma-like DALMs 
Sessile/pedunculated polyps 
Well circumscribed 
Smooth 
Clear borders 
Sessile (broad based) 
Poorly circumscribed 
Irregular surface 
Indistinct border 
Ulceration/necrosis 
Strictures 
Tethering 
Table 5. Features of DALMs 
(Blackstone et al., 1981). Others studies, report underlying carcinomas ranging from 34% to 
84% (Bernstein et al., 1994; Odze, 1999). DALMs can be further sub-classified into adenoma-
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like and non-adenoma-like features (Engelsgjerd et al., 1999; Odze et al., 2004; Rubin et al., 
1999). Adenoma-like features include well circumscribed, smooth or papillary, non-necrotic, 
sessile, or pedunculated polyps. Non-adenoma-like polyps include velvety patches, plaques, 
irregular bumps or nodules, wart-like thickening, stricturing lesions, and broad-based 
masses (Odze, 2008). The differentiation between adenoma-like and non-adenoma-like is 
based on gross endoscopic examination. Histologically both types of DALMs are made of 
tubular, tubulovillous or villous proliferation of adenoma epithelium with dysplastic 
columnar cells (Torres et al., 1998). 
4.5 Treatment of DALMs 
One of the challenges related to DALMs is the reliance on the endoscopist to differentiate 
adenoma-like lesions from a sporadic adenoma. Like the general population, sporadic 
adenomas increase with age and can be removed via polypectomy. However, some DALMs 
can develop features similar to a sporadic adenoma making it further difficult to 
differentiate the two (Guindi & Riddell, 2001; Torres et al., 1998). While there have been 
studies to differentiate sporadic adenomas from DALMs in UC patients, most did not 
achieve a level of certainty to confidently differentiate them (Bernstein et al., 1999; Torres et 
al.. 1998). The only aspect that seems to differentiate the two in UC are that adenoma-like 
lesions proximal to the start of the UC are likely sporadic adenomas (Torres et al., 1998).  
 
 
Fig. 1. Treatment algorithm for DALMs 
Until recently, treatment differed between sporadic adenomas and adenoma-like DALMs 
for which colectomy had been recommended. Thirty four patients with adenoma-like 
DALMs who underwent polypectomy were compared both to UC patients with sporadic 
adenomas who underwent polypectomy and non-UC patients with sporadic adenomas who 
DALM
Adenoma-like
Outisde area of 
known colitis
Polypectomy and 
routine 
surveillance
Within area of 
known colitis
Any area of flat 
dysplasia or 
negative margins
Yes
Colectomy
No
Polypectomy and 
routine/increased 
surveeillance
Non-adenoma-like
Colectomy
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underwent polypectomy. The development of recurrent polyps was 62.5% in the adenoma-
like DALM group, 50% in UC sporadic adenoma group and 49% in the non-UC sporadic 
adenoma control group (Engelsgjerd et al., 1999). In another study of eighty seven UC 
patients who underwent polypectomy, only 4.6% developed dysplasia during a mean 
follow up of six years (Vieth et al., 2006). Given that polypectomy for adenoma-like DALMs 
in UC patients affords similar protection against CRC as polypectomy for sporadic 
adenomas, current consensus recommendations support polypectomy for DALMs. 
Therefore, if an adenoma-like DALMs is completely resected endoscopically, with negative 
margins for dysplasia from biopsies around the lesion and no other findings of flat 
dysplasia in the colon, then routine surveillance following polypectomy is appropriate 
(Friedman et al., 2003; Odze et al., 2004; Rubin et al., 1999).  Similarly, any adenoma-like 
lesions outside the area of UC can be presumed to be sporadic in nature and treated with 
polypectomy and routine surveillance alone (Friedman, 2003). For adequate follow up 
surveillance, tattooing the adjacent mucosa to the resected polyps can aid in future 
identification and monitoring. 
In contrast, non-adenoma-like DALMs carry an unacceptable cancer risk (38% to 83%) even 
in those lesions considered endoscopically resectable. Therefore, any non-adenoma-like 
DALMs regardless of their sub-classification as low or high grade dysplasia necessitate 
colectomy. 
4.6 Flat dysplasia 
In cases of flat dysplasia, it is important to differentiate between high and low grade 
dysplasia. In small studies, high grade flat dysplastic lesions had concurrent CRC in 42% to 
67% of cases (Bernstein et al., 1999; Connell et al., 1994; Hata et al., 2003). In another study, 
patients who underwent colectomy for high grade dysplasia, 45% were found to have CRC 
noted on pathology (Rutter et al., 2006). In patients with high grade dysplasia who chose not 
to undergo colectomy, 25% to 32% of the cases progressed to CRC (Bernstein et al., 1999; 
Rutter et al, 2006). Given the high risk for synchronus CRC associated with high grade 
dysplastic lesions, and the significantly increased risk of progression to CRC, current 
consensus opinions recommends colectomy.  
With regards to low grade flat dysplasia, however, the evidence is more equivocal. Low 
grade dysplasia can be viewed as an intermediate step in the development of CRC, or it 
alone may be a marker for synchronous undiagnosed high grade dysplastic lesions or 
cancer. (Bernstein et al., 1994; Gorfine et al., 2000; Rutter et al., 2006). Studies vary regarding 
the risks of low grade dysplasia with some equating it to the risk of high grade dysplasia 
while others find it no more concerning than patients with no dysplasia. Small studies 
including patients who underwent colectomy for low grade dysplasia found synchronous 
CRC in 19% to 27% of patients (Bernstein et al., 1994; Farraye et al., 2010; Rutter et al., 2006). 
A more recent meta-analysis by Thomas et al. included 20 surveillance studies of flat low 
grade dysplasia or low grade dysplasia DALMs, and found a cancer incidence of 14 per 
1000 patient years and 30 per 1000 patient year incidence of advanced lesions (high grade 
dysplasia or CRC). When low grade dysplasia was detected on colonoscopy it was 
associated with a nine fold increased risk of developing CRC, and 12 fold risk of 
developing advanced lesions. For patients who opt to avoid colectomy and prefer 
continued surveillance of flat dysplasia, according to this meta-analysis the positive 
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predictive value for progression to high grade dysplasia or CRC is approximately 14.6% 
(Thomas et al., 2007). Other studies list rates of progression to neoplasia ranging from 33% 
to 54% (Rutter et al., 2006; Ullman et al., 2002). Other studies suggest that the risk of 
progression from low grade dysplasia to high grade dysplasia or CRC is actually much 
lower. In a study of patients with long standing extensive UC, the risk of progression to 
CRC in patients with low grade dysplasia was 10% while patients with extensive UC but 
no dysplasia progressed to CRC in 4% of the cases. This study concluded that the risk of 
progression is not much higher than in patients with no dysplasia (0.8 to 3%) and 
therefore prophylactic colectomy is not appropriate (Lim et al., 2003). Moreover, another 
study did not find any cases of low grade dysplasia progressing to CRC (Befrits et al., 
2002). Since the actual risk of progression is unclear, consensus recommendations favor 
discussion with the patients and informing them of the risks and benefits of surveillance 
versus early colectomy. A medical decision analysis of 10,000 patients with UC was 
performed to assess patient preference when faced with the decision between surveillance 
and colectomy for unifocal low grade dysplasia. Overall patients preferred immediate 
colectomy, with slight increase in quality adjusted life years and overall lower costs of 
treatment (Nguyen et al., 2009).  
4.7 Prevalent versus incident dysplasia 
Dysplasia is further classified based on when it was found on endoscopic exam. Dysplasia 
detected on initial colonoscopy is referred to as prevalent dysplasia. Prevalent dysplasia 
carries a higher rate of progression to CRC. When prevalent low grade dysplasia was found 
29% of patients progressed to high grade dysplasia or CRC during follow up (Bernstein et 
al., 1994).  In contrast, dysplasia that was detected on subsequent surveillance 
colonoscopy is referred to as incident dysplasia. When incident low grade dysplasia was 
found, only 16% of cases progressed to high grade dysplasia or CRC. In comparison, if no 
dysplasia was noted on initial colonoscopy, the risk of subsequent CRC ranged from 1.1% 
to 3.1% (Bernstein et al., 1994; Connell et al., 1994; Lindberg et al., 1996; Nugent et al., 
1991). 
4.8 Interobserver variability in grading of dysplasia  
Unfortunately, there is significant variability in pathologists’ agreement in the grading of 
dysplasia, ranging from 42 to 65% (Melville et al., 1989). This is most prominent in non-
gastrointestinal specialized pathologists and between the classification of marked 
regenerative changes versus low grade dysplasia and between the classification of high 
grade dysplasia and invasive adenocarcinoma (Riddell et al., 1983). Interobserver studies 
show only moderate levels of agreement between pathologists’ interpretations (Dixon et al., 
1988; Eaden et al, 2001b; Melville et al., 1989; Odze et al., 2002). The levels of agreement were 
lowest in cases of indefinite dysplasia and low grade dysplasia. Unfortunately, even with 
experienced pathologists, there still remain a significant amount of interobserver variability 
between indefinite versus low grade (Melville et al., 1989). In contrast, the interobserver 
validity between negative and high grade dysplasia is quite good (Dixon et al., 1988). Given 
that treatment decisions are made based on the degree of dysplasia, consensus 
recommendations recommend that a pathologist specializing in gastroenterology review 
and confirm any cases of dysplasia (Itzkowitz & Present, 2005).   
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Levels of dyplasia Interobserver validity 
Indefinite for dysplasia vs. Low grade dysplasia 
High grade dysplasia vs. Carcinoma 
Negative for dysplasia vs. High grade dysplasia 
Poor 
Poor 
Good 
Table 6. Interobserver validity based on level of dysplasia 
4.9 Molecular markers 
In order to reduce interobserver variability molecular and non-molecular markers have been 
evaluated to aid in the diagnosis of dysplasia. Majority of the studies on tumor markers are 
tested from the biopsy samples of dysplasia or no dysplasia which unfortunately does not 
provide information on the evolution of the dysplasia. Few studies have been designed to 
study patients longitudinally over time to detect the early expression of tumor markers. The 
markers that have been evaluated in this format showing increased risk of CRC include 
aneuploidy, p53, MSI and mucin-associated STn antigen (Farraye et al., 2010). Aneuploidy is 
an early event in the carcinogenesis pathway often occurring before or coincident with the 
initial detection of dysplasia (Rubin et al., 1992). Similarly, p53 mutation is also an event that 
is likely preceding the dysplasia and is an important step in the carcinogenesis progression 
(Lashner et al., 1999). In some of the patients the p53 mutation was detected eight months to 
two years prior to dysplastic changes (Ilyas & Talbot, 1995; Lashner et al., 1999). Patients 
with this mutation had a relative risk of developing dysplasia or cancer of 4.53 (95% CI 2.16-
9.48) and was associated with cancer related mortality (Lashner et al., 1999). Likewise, 
patients who develop microsatellite instability CRC already expressed these changes in non-
dysplastic tissue ranging from two to twelve years prior to the diagnosis of CRC (Tahara et 
al., 2005). The STN antigen expression occurs frequently in dysplastic lesions that often 
occur earlier than the aneuploidy changes (Karlen et al., 1998b). While these markers seem 
to portend a poor prognosis like p53, they are not incorporated yet into the overall 
assessment to choose between colectomy and continued surveillance. The added benefits of 
these makers are their noted presence in the mucosa long before carcinoma develops. Such 
an aid could assist pathologists in being more precise in their grading of dysplasia. 
However, further studies are still needed to determine the niche of molecular profiling in 
CRC surveillance and risk stratification.  
 
Molecular Markers to assist in determination of dysplasia 
AMACR 
Aneuploidy 
p53 
MSI 
Mucin-associated STn antigen
Table 7. Potential molecular markers to aid in determination of dysplasia 
A potentially promising biomarker is the α-methylacyl-CoA racemase (AMACR). This 
marker is not found in any non-dysplastic tissue. It is significantly increased in areas of low 
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grade dysplasia (96%), high grade dysplasia (80%) and adenocarcinoma (71%). This marker 
was only found in 14% of cases of indefinite for dysplasia, but was only focally and weakly 
positive.  In attempting to differentiate high grade dysplasia the specificity is nearly 100% 
with a sensitivity of 80 to 96% (Dorer & Odze, 2002). While more studies are still needed, 
this marker does have the potential to significantly assist pathologists in determination of 
dysplasia versus no dysplasia. 
5. Surveillance colonoscopy  
While enhanced surveillance colonoscopy in patients with UC is presumed to reduce the 
risk of developing CRC, it has not been proven through randomized control trials. Only case 
series suggest a possible benefit (Eaden et al., 2000a; Lofberg et al., 1990; Nugent et al., 1991). 
A Cochrane database review of these trials in 2004 revealed a reduction in CRC mortality in 
those patients who underwent at least one screening colonoscopy with a relative risk of 0.28 
(95% confidence interval 0.07 to 1.17). This effect was more pronounced in those who had at 
least two screening colonoscopies (RR 0.22 95% confidence interval 0.03 to 1.74). This effect 
was less notable for patients who only had one colonoscopy (RR 0.43 95% confidence 
intervals 0.05 to 3.76). Unfortunately though, all the confidence intervals crossed 1. As a 
result, the study concluded that there is no clear evidence that surveillance colonoscopy 
prolongs patient survival. While cancer is detected at an earlier stage in patients with a 
better prognosis who undergo surveillance screening, there is concern that lead time bias 
may cause this affect. It seems likely, though, that screening reduces the risk of death and 
may be cost effective as well. (Mpofu et al., 2004).  
5.1 Surveillance colonoscopy recommendations 
While classic CRC screening recommends colonoscopy once every ten years given the slow 
evolution of adenoma to carcinoma, in UC this interval is less clear. Some studies have 
noted new pathology within one to two years of a reported negative colonoscopy (Connell 
et al., 1994; Lim et al., 2003). Therefore, surveillance colonoscopy initiation and interval 
follow up is tailored to the patients underlying risks. All patients with UC should undergo a 
screening colonoscopy at eight years to ten years after the onset of symptoms with 
appropriate biopsies to determine the true extent of any microscopic disease (Eaden & 
Mayberry, 2002).  
Extent of disease, which helps determine follow up interval, is based on the most proximal 
disease noted histologically at any point in the patient’s disease. If the patient’s disease is 
isolated proctitis or proctosigmoiditis then UC specific related screening can be terminated. 
As mentioned earlier, these isolated conditions do not convey a significantly increased risk 
of UC-related CRC. These patients should follow routine screening CRC prevention 
guidelines starting at age 50 unless the patient has a concerning family history necessitating 
earlier screening as per CRC screening guidelines. 
If the UC is classified as pancolitis or left sided colitis with negative initial screening, the 
follow up colonoscopies should be performed every one to two years. In patients who have a 
negative initial screening colonoscopy, follow up exams should be performed every one to two 
years until the patient has two negative examinations. After two negative exams, surveillance 
can be spread to over one to three years until the duration of disease has existed for twenty 
years. At that time, interval surveillance should be narrowed again to every one to two years. 
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Patients with associated primary sclerosing cholangitis carry a significantly increased risk of 
CRC and therefore should begin indefinite screening immediately at the time of diagnosis 
and every year thereafter. Other high risk patients, like those with a family history of CRC 
in first degree relatives, ongoing active inflammation (either endoscopic or histologic), 
foreshortened colon, strictures, or multiple inflammatory pseudopoyps all may benefit from 
more frequent surveillance exams. However, the exact interval follow up is unclear (Farraye 
et al., 2010; Itzkowitz & Present, 2005). 
 
Initial screening colonoscopy Screening recommendations 
Ulcerative colitis screening colonoscopy Initiate 8-10 years after onset of disease 
Associated Primary sclerosing cholangitis Initiate at time of diagnosis 
Interval follow up screening after initial 
negative screening colonoscopy 
 
UC patient with negative initial screen Continue surveillance intervals every 1-2 
years until 2 negative exams 
then interval screening is every 1-3 years. 
UC patient with 20 years duration of disease Re-start surveillance intervals every 1-2 
years  
UC patient with Extensive/Left sided colitis Continue regular surveillance intervals 
every 1-2 years 
UC patient with PSC Continue surveillance every year 
UC patient with family history of CRC, active 
inflammation, foreshortened colon, strictures, 
multiple inflammatory pseduoplyps 
May benefit from more frequent 
surveillance. Exact interval surveillance 
is unclear. 
UC patient with isolated 
Proctitis/Proctosigmoiditis 
Screen per guidelines for age-specific 
CRC (no increased surveillance) 
Table 8. Summary of screening and follow up surveillance recommendations 
The British Society of Gastroenterology updated their screening recommendations in 2010. 
The updates to their guidelines include initiating screening approximately ten years after 
disease onset. Also, surveillance colonoscopies should only be performed during disease 
remission, but should not be unduly delayed. Importantly, the risk of cancer is influenced 
by duration and extent of disease and additional risk factors like primary sclerosing 
cholangitis and family history of colorectal cancer. Also, both histologic and endoscopic 
features can also portend an increased risk of CRC. Patients at high risk should have yearly 
exams, moderate risk every three years, and low risk every five years. Newer modalities of 
screening are also incorporated in the new guidelines. Pancolonic dye spraying with 
targeted biopsies of the abnormal area should be performed. If chromoendoscopy is 
available then it should be used. Otherwise two to four random biopsies of every 10 cm of 
colon should be obtained. However, in areas of concern, additional biopsy samples should 
be taken. Finally, if dysplastic lesions can be completely removed it is not necessary to 
recommend colectomy (Cairns et al., 2010).  
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5.2 Management of dysplastic lesions 
In the event that flat high grade dysplasia is noted anywhere in the colon and confirmed by 
an expert gastrointestinal pathologist, colectomy is the treatment of choice (Farraye et al., 
2010; Thomas et al., 2007). Similarly, multifocal low grade dysplasia is also considered a 
strong indication for colectomy. Those with pathology termed indefinite for dysplasia 
should undergo a repeat examination in three to twelve months (Farraye et al., 2010). It is 
unclear if colectomy or enhanced surveillance should be performed for flat unifocal low 
grade dysplasia given the potential progression to high grade dysplasia or CRC. If 
surveillance is chosen, follow up colonoscopy should be done within three to six months. 
Discussion about risks and benefits of colectomy versus closer surveillance must be 
discussed with the patient. Similarly, it is unclear if recurrent findings of flat low grade 
dysplasia on serial colonoscopies increase the risk of synchronous or metachronous CRC 
compared to the risk associated with the finding of an isolated flat low grade dysplasia. A 
similar discussion with the patient regarding risks and benefits of screening versus 
colectomy should be done. 
 
 
Fig. 2. Management of dysplasia (For DALM management see figure) 
5.3 Factors involving successful endoscopy 
There are a number of factors that affect the success rate of a screening colonoscopy 
program. The initial detection of potentially dysplastic lesions relies on endoscopist skill and 
technique. Unlike sporadic adenomas, some lesions in UC may be flat and difficult to detect. 
Overall though, up to two thirds of dysplastic lesions are visible on endoscopy (Rutter et al, 
2004b). However, a sizable number of potentially dysplastic lesions are missed on routine 
endoscopic visualization. As a result, a number of newer techniques are being developed to 
enhance the detection of the remaining dysplastic lesions. Another challenge is the ability to 
Dysplasia
High grade dysplasia
Colectomy
Multifocal low grade 
dysplasia
Colectomy
Unifocal low grade 
dysplasia
Discuss with patient risk 
of progression to cancer
Choose either:
Colectomy 
Close surveillance 
repeat colonoscopy 3-6 
months
Indefinite for dysplasia
Repeat colonoscopy within 
3-12 months
consider 3-6 if concern it 
may be positive
consider 6-12 if probably 
negative
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completely resect suspected lesions. While prior studies had recommended colectomy for 
DALMs, newer studies have demonstrated equal success with complete polypectomy 
(Engelsgjerd et al., 1999; Vieth et al., 2006). The importance of complete resection is crucial to 
the success of a surveillance program. Any lesion that cannot be completely resected, should 
negate continued surveillance and proceed to colectomy. Lastly, the endoscopic must 
comply with the current consensus recommendations when using their recommended 
intervals. Overall adherence to consensus guidelines is quite poor (Bernstein et al., 1995; 
Eaden et al., 2000b). 
5.4 Adequate sampling of mucosa 
Given that microscopic disease can occur anywhere in the colon, multiple biopsies must be 
obtained to achieve adequate surveillance. Thirty three samples yielded a 90% probability of 
detecting any present dysplasia, while sixty four samples yield a 95% probability of 
detecting dysplasia if present (Rubin et al., 1992). A total of two to four samples should be 
taken from all four quadrants from every ten centimeters of colon (Itzkowitz & Harpaz, 
2004). Careful examination and sampling of the rectosigmoid region is crucial as this area 
has a predominance of neoplasia in UC (Choi, 1993). These specimens should be collected in 
individual jars to assist in localizing the specimen back to the colonic segment if further 
monitoring is warranted. The ideal time for surveillance screening with random biopsy 
sampling should be when the patient is in a state of clinical remission. Active inflammation 
creates difficulty in distinguishing reactive epithelium from dysplasia (Eaden & Mayberry, 
2002). Nonetheless, even with extensive biopsies of the colon, it is still only a small fraction 
of the entire colon that is sampled (approximately 1%) (Itzkowitz & Harpaz, 2004). Given 
that dysplasia is most often unifocal in nature, it is still quite possible to miss the one 
location that has high grade dysplasia or carcinoma. Another complicating factor is that 
despite consensus recommendations regarding biopsy sampling, surveys of 
gastroenterologists’ biopsy practices in the United States and United Kingdom demonstate 
poor adherence to these recommendations, further lowering the probability of detecting 
dysplasia (Bernstein et al., 1995; Eaden et al., 2000c). As newer endoscopic modalities like 
chromoendoscopy and narrow band imaging are being developed, more targeted biopsies 
will be possible with the goal of overall improved surveillance of the entire colon. 
5.5 Anatomic factors complicating surveillance 
Adequate surveillance is also limited by anatomic factors. Presence of either psuedopolyps 
or strictures has been reported to increase the risk of CRC by two fold and four fold 
respectively (Rutter et al., 2004c). Other reports found up to 24% of strictures may be 
malignant (Gumaste et al., 1992). Additionally, strictures throughout the colon may limit the 
endoscopists ability to adequately maneuver around them limiting the comprehensiveness 
of the surveillance examination. 
6. Assessment, cost and safety, and hurdles to successful screening 
program 
The key features of any surveillance program include (1) a disease with a high prevalence in 
the selected patient population; (2) a screening test that is highly sensitive and specific, (3) 
low cost, (4) safe, and (5) acceptable to both the patient and the practitioner. The early 
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detection of disease should then enable early treatment of the disease to ideally prolong 
survival (Wilson, & Jungner, 1968). The prevalence of UC associated CRC, and the 
knowledge that dysplastic changes occur in the colon prior to symptoms provides the 
background for instituting a screening program. However, the costs, risks and associated 
hurdles all need to be evaluated for the program to be effective.  
6.1 Assessment of surveillance programs 
Evaluating the success of surveillance programs has been challenging for numerous reasons. 
The timeframe needed to assess the impact on patients requires approximately fifteen to 
twenty years (Eaden & Mayberry, 2000). Also, patient compliance over this prolonged 
period of time is challenging, necessitating multiple visits for follow up colonoscopies. 
Another confounder is varying treatment recommendations from physicians. As discussed 
previously, adherence to guideline recommendations is variable. There are some centers 
that recommend early colectomy for dysplasia resulting in overall lower rates of cancer but 
at a significant morbidity cost. Finally, randomization is impractical given the ethical issues 
related to placing high risk patients in control arms (Eaden & Mayberry, 2000). While some 
studies of screening endoscopies found earlier cases of cancer, this was only in a minority of 
patients with a high cost-to-benefit ratio (Axon, 1994; Collins et al., 1987; Gyde, 1990). 
Conversely, a small US study attributed early cancer detection to surveillance with a five 
year survival rate of 77% in the surveillance group compared to 36% in the control group 
(Choi, 1993). Other studies that did not find any significant benefit in detection of CRC still 
found a much lower mortality in the screened group due to associated clinical reviews of 
their disease and management (Connell et al., 1993; Karlen et al., 1998a). However, a 
Cochrane meta-analysis failed to show a benefit for surveillance screening colonoscopies to 
prevent CRC-related death (Rutter et al., 2006).  
6.2 Safety and cost effectiveness of surveillance  
The overall morbidity associated with surveillance colonoscopy is extremely low. The 
overall complication rate after 379 surveillance colonoscopies was one silent perforation, or 
0.26% (Koobatian & Choi, 1994). Similar findings were noted in a British study of 811 
surveillance colonoscopies (Lennard-Jones et al., 1990). Using decision analysis to provide 
indirect evidence of CRC screening effectiveness, Provenzale et al found life expectancy 
increased 1.2 years with screening (Provenzale et al., 1995). The overall cost of the 
surveillance program is difficult to estimate. The costs of the surveillance program need to 
include not only the medical costs, but also the patients time undergoing the test, travel, lost 
earnings, and, the more difficult to assess, patient anxiety and discomfort (Eaden & 
Mayberry, 2000). One US study using a hypothetical scenario of a screening system that 
found all cancerous lesions in 1000 patients over a ten year period estimated the cost for 
each cancer found or prevented to be $200,000 (based on cost data from 1983). However, this 
price does not account for the patient costs or potential complications when performing the 
numerous colonoscopies. In this study, an estimated 9,775 colonoscopies were performed to 
locate or prevent a cancer. However, with a perforation rate of 0.2 to 0.4 roughly three 
patients would need emergent treatment for perforated colon adding to the overall 
screening cost (Collins et al., 1987; Eaden & Mayberry, 2000; Katzka et al., 1983). A more 
recent study comparing endoscopic cancer screening tests found a theoretically lower cost. 
Using an estimated risk of UC related CRC of 1%, and with performingcolonoscopies every 
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two years, they found that 1.4 to 2 cancers per 100 endoscopies would be detected. The 
overall cost of the procedure alone was $71,000 per cancer detected (Sonnenberg & El-Serag, 
1997). Unfortunately, these numbers are only hypothetical costs of the procedures alone in a 
100% successful screening system.  
6.3 Hurdles to successful screening surveillance program 
Crucial to any screening program is the ability of the endoscopist to accurately biopsy the 
colon and the pathologist to accurately diagnose dysplasia. Discussed early in this chapter, 
the interobserver variability amongst pathologists can limit the successful diagnosis of 
dysplasia and appropriate treatment recommendations. Furthermore, despite consensus 
guidelines published by both European and US societies, there still remains significant 
variability amongst gastroenterologists’ compliance with these recommendations. In one 
study of US gastroenterologists, only 19% correctly defined dysplasia. Within this group 
48% accurately defined high grade dysplasia and only 16% defined low grade dysplasia. 
When choosing treatment options, nearly one third of gastroenterologists recommended 
continued surveillance despite a diagnosis of high grade dysplasia (Bernstein et al., 1995). In 
a British study, only 53% of gastroenterologists recommended colectomy for high grade 
dysplasia (Eaden et al., 2000b). A more recent study of both colorectal surgeons and 
gastroenterologists from New Zealand similarly found poor knowledge of the definition of 
dysplasia, with only 20% responding correctly. In this group, the colorectal surgeons 
defined dysplasia correctly more often and understood the significance of low grade 
dysplasia as well (Geary et al., 2004). Despite clear recommendations from the American 
Gastroenterological Association to perform four quadrant biopsies every ten cm for a total 
of thirty to forty biopsies, only 41% of gastroenterologists followed this recommendation. 
52% of the gastroenterologists only took two to four biopsies and 6% did not follow any 
protocol. Overall, 73% of the gastroenterologists performed less than thirty biopsies per 
colonoscopy (van Rijn et al., 2009) . In assessing the overall adequacy of surveillance, 33% of 
patients received inadequate surveillance for CRC (Reddy et al. 2005; Obrador et al., 2006). 
In 2009, Kottachchi et al. performed a retrospective study after the publication of the 
Canadian Association of Gastroenterology screening guidelines and found that the overall 
adherence improved with 74% of patients receiving follow up surveillance appropriately 
(Kottachchi et al., 2009). Ultimately, the overall education and continued education in 
association with consensus guidelines is crucial to adequate screening. 
6.4 Patient adherence 
Another major hurdle to successful surveillance is patient acceptance of the surveillance 
process. Multiple aspects of the screening program can create challenges for patients to 
comply with the screening. Close follow up colonoscopies require patients to repeat bowel 
preparations, return to clinic, and find a chaperone to take them home. All of these steps are 
potential pitfalls for patient compliance. Unfortunately, most of these steps cannot be altered 
to improve patient compliance. However, studies evaluating patient compliance in routine 
CRC screening found a positive association between knowledge and screening behavior 
(Vernon, 1997). The lack of knowledge is most prominent among minorities and those of 
low socioeconomic status (Beeker et al., 2001; Lipkus et al., 1996; Price, 1993).  Patients need 
counseling regarding the importance of CRC surveillance as well as the understanding of 
the predictive value of the colonoscopy to effectively rule out potential cancer. 
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Unfortunately, if patients do not adhere to the surveillance recommendations negative 
consequences may occur (Connell et al., 1994; Lindberg et al., 1996).  
 
Barriers to screening 
Definition of dysplasia 
Differentiating subtypes of dysplasia 
Appropriate number of biopsies 
Adherence to guidelines  
Surveillance 
Treatment 
Patient specific barriers 
Lack of knowledge 
Preferences 
Non-compliance with recommendations 
Table 9. Barriers to screening 
7. Newer imaging modalities 
Given that up to 1/3 of dysplasia is not detected on endoscopic examination, better 
diagnostic modalities are needed in place of just random biopsies. Without improved 
diagnostic techniques, a negative exam from random biopsies could convey a false sense of 
reassurance. Newer modalities attempt to delineate those lesions that are subtle but present 
at the layer of the mucosa, or even deeper providing the endoscopist with both subsurface 
analysis and instant histologic analysis. Such newer techniques combining both random 
biopsies with more focused examination would theoretically provide a more thorough and 
accurate screening process. Newer modalities are sometimes used alone or in combination 
and include chromoendoscopy with pancolonic dye spraying, autofluorescene, confocal 
laser endomicroscopy, narrow band imaging, and optical coherence tomography. 
7.1 Chromoendoscopy 
Chromoendoscopy is a technique that has already been used in Europe and Asia, and more 
recently in the US, to help identify non-polypoid flat and depressed potentially neoplastic 
lesions (Soetkino et al., 2006). Chromoendoscopy involves applying mucosal stain or 
pigment by injecting dye down an endoscopic spray catheter. Indigo carmine is one type of 
dye which coats the colonic mucosal surface enabling the endoscopist to visualize subtle 
disruptions in the normal contours of the mucosa. Another dye, methylene blue, is avidly 
absorbed by non-inflamed mucosa and poorly taken up by inflamed mucosa and dysplastic 
lesions. The dyes improve the detection of subtle colonic lesions enabling increased 
sensitivity of screening colonoscopy. Additionally, chromoendoscopy can differentiate 
neoplastic from non-neoplastic lesions based on the crypt architecture utilizing the modified 
pit pattern classification (Rutter, 2010). This is further improved when using a magnifying 
colonoscope (Kudo et al., 2001). These techniques enable the endoscopist to obtain targeted 
biopsies after pancolonic dye spraying, improving overall sensitivity of the exam (Kiesslich 
et al., 2003; Marion et al., 2008; Mastumoto et al., 2003; Rutter et al., 2004a). 
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Chromoendoscopy is also able to provide a more accurate determination of extent of disease 
as well as degree of inflammation (Kiesslich et al., 2003). The superiority of focused biopsies 
utilizing methylene blue was supported in a study noting a three fold increase in dysplasia 
detection compared to random biopsies alone (Kiesslich et al., 2003). In comparing the 
diagnostic yield to standard colonoscopy, panchromoendoscopy with indigo carmine dye 
increased the diagnostic yield of dysplasia 3.5 to 4.5 fold (Rutter et al., 2004a). A different 
study compared 350 patients with long standing UC undergoing surveillance using 
chromoendoscopy and a high magnification colonoscope to 350 matched UC control 
patients undergoing standard white light colonoscopy and found that the enhanced 
screening technique yielded more dysplastic lesions. However, this enhanced detection was 
at the cost of significantly longer extubation times (average of 24 minutes compared to 13 
minutes in the control group) (Hurlstone et al., 2005). 
7.2 Autofluorescene imaging 
A different imaging enhanced modality, autofluorescene imaging, in a small study showed 
improved detection of dysplastic lesions compared to routine endoscopy (van den Brock et 
al., 2008). The sensitivity for detecting dysplastic lesions ranged from 87% to 100% after local 
sensitization (Kiesslich et al., 2008). However, current guidelines do not currently 
incorporate this method into their screening recommendations and more studies are needed 
to assess its overall utility and cost effectiveness.  
7.3 Confocal laser endomicroscopy 
A newer method, confocal laser endomicroscopy, allows subsurface analysis of intestinal 
mucosa and analysis of the underlying histology during the endoscopy (Kiesslich et al., 
2008). This is attached to a standard endoscope and used in conjunction with a system 
fluorescent contrast agent or topical agent sprayed on mucosa. The images provide real-time 
information regarding cellular and vascular changes. The sensitivity reached 97.4% with a 
specificity of 99.4% and an accuracy of 99.2% (Kiesslich et al., 2007). This method can be 
used in conjunction with chormoenedoscopy which will help identify circumscript lesions, 
while the laser endomicroscopy is able to predict the intraepithelial neoplasias (Kiesslich et 
al., 2008). In a study comparing the combination of panchromoendoscopy and 
endomicroscopy compared to conventional colonoscopy, the combined modality found 
significantly more intraepithelial neoplasia (19 versus 3 p value 0.007) but had an 11 minute 
longer average extubation time (42 minutes versus 31 minutes). This technique provided a 
4.75 fold increase in detected dysplastic lesions while needing 50% fewer biopsy specimens 
(Kiesslich et al., 2007).   
7.4 Narrow band imaging, optical coherence tomography 
Other modalities like narrow band imaging which uses optical technology to visualize 
microvascular structures of the mucosal layers has not been shown to be superior to 
standard colonoscopy (Dekker et al., 2007). Another method, optical coherence tomography, 
utilizes an optical analog of ultrasound to allow for cross-sectional images of the luminal 
gastrointestinal tract. This too does not yet provide satisfactory resolution to enhance 
surveillance over routine colonoscopy (Kiesslich et al., 2008). 
Given that all these techniques are still relatively new, it has not been proven yet if the 
increased sensitivity in locating dysplastic lesions in fact prolongs survival. Also, as white 
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light endoscopy technology continues to improve, it is unclear how many additional lesions 
will still be found when newer white light endoscopes are studied in comparison to 
chromoendoscopy (Farraye et al., 2010).   
8. Chemoprevention 
In the non-UC population, chemoprevention using cox-2 inhibitors or aspirin has been 
evaluated with success (Arber & Levin, 2008). In UC, chemoprevention is of particular 
interest for its potential to reduce the risk of CRC. Similar to sporadic CRC, the presumed 
initial insult is chronic inflammation. As a result, chemoprevention in UC has also focused 
on anti-inflammatory agents. Aminosalicylates, corticosteroids, folic acid, 
immunomodulators, and UDCA have all been studied. 
8.1 Ursodeoxycholic acid (UDCA)  
As mentioned earlier, UC patients with associated PSC are at the highest risk of CRC. 
UDCA is already used to treat the cholestatic affects of primary sclerosing cholangitis. 
Retrospective analysis of patients already taking UDCA and with concomitant UC found a 
strong decreased incidence of colonic dysplasia with an odds ratio of 0.18 (95% CI 0.05-0.61) 
(Tung et al., 2001). This was confirmed in a prospective study out of Mayo Clinic showing a 
similar reduction in dysplasia and cancer (Pandi et al., 2003). Unfortunately though, there 
have been conflicting studies performed showing no chemopreventive effects from the 
UDCA (Shetty et al., 1999; Wolf et al., 2005). UDCA has also been evaluated in patients with 
UC with no associated PSC. A small study in Sweden found potential benefits after two 
years of treatment with UDCA; in the ten patients who took UDCA, none developed high 
grade dysplasia or cancer (Sjoqvist et al., 2004). The underlying mechanism of UDCA is 
unknown, but it may decrease bile acids like deoxycholic acid which may have carcinogenic 
potential.  
8.2 Aminosalicylates 
Aminosalicylates are used for maintenance therapy in many patients with UC for prolonged 
periods of time. Studies in England have shown a 75 to 90% reduction in the incidence of 
CRC (Eaden et al., 2000a). Both mesalazine and sufasalazine have chemoprotective effects 
with dose response effect. Mesalazine was somewhat superior and reduced cancer by 81% at 
doses > 1.2 grams daily (Moody et al., 1996; Rubin et al., 2006b; van Staa et al., 2005). Also, 
the longer the duration of mesalazine use, the more pronounced the effect (van Staa et al., 
2005).  Other studies have noted 60% to 72% risk reduction rates of CRC with the use of 
mesalamine. This benefit was separate from the risk reduction associated with surveillance 
colonoscopy (Rubin et al., 2006b; Velayos et al., 2006). Unfortunately, this benefit is lost with 
cessation of the drug as noted in a retrospective study with only 3% of patients on 
mesalamine developing CRC compared to 31% of patients who stopped or could not 
comply with treatment (Moody et al., 1996). Similar to the UDCA, there are some conflicting 
studies which did not achieve risk reductions of CRC with any statistical significance 
(Bernstein et al., 2003; Lindberg et al., 2001; Ullman et al., 2008). A large meta-analysis of the 
studies using mesalamine showed a preventative effect for CRC with mesalamine use (OR 
0.51; 95% CI, 0.37-0.69) and for CRC plus dysplasia (OR 0.51; 95% CI, 0.38-0.69). However, 
mesalamine did not lower the overall risk of dysplasia (OR 1.18; 95% CI, 0.41-3.43) (Velayos 
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et al., 2005).  Given this understanding of mesalamine being protective against CRC but not 
specifically for dysplasia, it is unclear when mesalamine treatment provides the greatest 
chemopreventive benefits in the dysplasia-carcinoma sequence. In one retrospective study 
of high and low dose mesalamine in patients with no dysplasia, indefinite dysplasia, and 
low grade dysplasia, the largest benefit was found in patients taking high dose mesalamine 
(>2grams per day) and no dysplasia or indefinite for dysplasia (Ullman et al., 2008). Based 
on this study it is hypothesized that the most benefit is found early on in the dysplasia-
carcinoma sequence prior to any significant dysplastic changes. The underlying mechanism 
of action of the anti-neoplastic effects has been postulated to be its potential anti-
inflammatory activity, promotion of apoptosis of CRC tissue with no effect on normal 
mucosa, or improved DNA replication fidelity in CRC cells. 
8.3 Corticosteroids and Nonsteroidal anti-inflammatory drugs (NSAID) 
Continuing with the anti-inflammatory hypothesis to reduce CRC risk, corticosteroids have 
been evaluated given their known anti-inflammatory effects. While not the primary end-
point, most studies have found no chemoprotective effect with the use of corticosteroids. 
However, some studies found a 60% risk reduction with the use of oral prednisone for 
greater than one year (OR 0.4; 95% CI 0.2 to 0.8) (Velayos et al., 2006). However, regardless 
of the potential treatment benefit, the toxicity associated with chronic steroid use limits the 
benefits of this potential treatment. While NSAID use has been show to be chemoprotective 
in sporadic CRC, its use in UC related CRC is less clear. A recent study of patients with a 
history of IBD and NSAID use did not achieve statistical significance (OR 0.47; 95% CI, 0.12-
1.86). The results, however, were suggestive of a potential risk reduction, but no definitive 
recommendations can be made (Samadder et al., 2011).  
8.4 Immunomodulators and biologic agents 
Since immunomodulators are the cornerstone of therapy for many patients with UC, their 
potential risk reduction benefits have been evaluated. In patients who were free of dysplasia 
neither 6-mercaptopurine (6-MP) nor azathioprine (AZA) showed any protection on 
progression to CRC after eight years (Matula et al., 2005). Among patients with extensive 
colitis and prolonged use of AZA, there was still no reduced cancer risk (Connell et al., 
1994). Even in high risk patients with associated PSC, use of AZA did not provide any 
chemopreventive benefits (Tung et al., 2001). Similarly, 6-MP did not find any CRC risk 
reduction, but importantly, it also did not show any increased risk of cancer in the setting of 
prolonged use (Korelitz et al., 1999). Given the lack of evidence supporting CRC risk 
reduction with immunomodulators, they cannot be recommended as chemoprophylaxis. 
8.5 Supplements (folic acid, calcium, and multivitamins) 
In sporadic CRC, folic acid deficiency has been associated with spontaneous CRC formation 
(Freudenheim et al., 1991). Patients with UC are predisposed to folate deficiency from both 
poor nutritional intake and intestinal losses associated with inflammation in active disease. 
Despite this, current studies encorporating folic acid supplementation have been suggestive 
of a potential benefit but did not achieve any statistically significant reduction (Lashner et 
al., 1989; Lashner et al., 1996). However, the potential benefit may be confounded due to 
many patients already taking multivitamins or eating bread that is fortified with folic acid. 
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Additionally, supplementing with calcium or multivitamins has also not been shown to 
reduce overall cancer risk in UC (Farraye et al., 2010). 
8.6 Statins 
More recently, statin therapy has been evaluated as a possible chemopreventive agent. In a 
case control study based in Israel of a colorectal cancer registry, patients on long term statin 
use had a reduced risk of developing CRC. In this study, patients with IBD had an overall 
1.9 fold increased risk of developing CRC. This was attenuated though with long term statin 
use (OR 0.07; 95% CI 0.01-0.78) (Samadder et al., 2011). Statin use for five years was found to 
have a large risk reduction of 94% in patients with IBD (Poynter et al., 2005). 
 
Agents Chemoprotective benefit 
Aminosalicylates Likely chemoprotective 
UDCA Chemoprotective with comorbid PSC 
Potentially chemoprotective with UC alone 
Statins Potentially chemoprotective 
Corticosteroids Toxicity outweights any benefit 
NSAID Unclear 
Immunomodulators No effect 
Folic acid Unclear 
Calcium No effect 
Multivitamin No effect 
Table 10. Chemoprotective effects of different agents 
9. Conclusion 
Patients with UC are at increased risk of CRC relative to the general population. The overall 
risk is still unclear and ranges from a mild to significantly increased risk relative to the 
general population. Specific patient risk factors including extent of disease, duration of 
disease, severity of inflammation, age of onset, family history, and associated PSC all 
increase the risk of CRC. With this increased risk, UC related cancer screening is 
recommended. More specific recommendations are still needed to help analyze the 
individual UC patient’s risk profile when determining appropriate screening intervals. 
Additionally, both gastroenterologists and pathologist need continued training on current 
guidelines and definitions for dysplasia. With improved adherence to guidelines, and 
correct interpretation of dysplasia, more appropriate treatment can be initiated. The ultimate 
goal in UC patients is to lower their risk for CRC to that of the general population. 
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